Optimization of 1,3,4-Benzotriazepine-Based CCK2 Antagonists to Obtain Potent, Orally Active Inhibitors of Gastrin-Mediated Gastric Acid Secretion

Starting from a novel, achiral 1,3,4-benzotriazepine-based CCK2 receptor antagonist, a process of optimization has afforded further compounds of this type that maintain the nanomolar affinity for recombinant, human CCK2 receptors and high selectivity over CCK1 receptors observed in the initial lead...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2007-06, Vol.50 (13), p.3101-3112
Main Authors: McDonald, Iain M, Black, James W, Buck, Ildiko M, Dunstone, David J, Griffin, Eric P, Harper, Elaine A, Hull, Robert A. D, Kalindjian, S. Barret, Lilley, Elliot J, Linney, Ian D, Pether, Michael J, Roberts, Sonia P, Shaxted, Mark E, Spencer, John, Steel, Katherine I. M, Sykes, David A, Walker, Martin K, Watt, Gillian F, Wright, Laurence, Wright, Paul T, Xun, Wei
Format: Article
Language:English
Subjects:
Biological and medical sciences
Digestive system
Medical sciences
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems
Pharmacology. Drug treatments
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Starting from a novel, achiral 1,3,4-benzotriazepine-based CCK2 receptor antagonist, a process of optimization has afforded further compounds of this type that maintain the nanomolar affinity for recombinant, human CCK2 receptors and high selectivity over CCK1 receptors observed in the initial lead but display more potent inhibition of pentagastrin-stimulated gastric acid secretion in vivo. Moreover, this has largely been achieved without altering their potency at wild-type canine and rat receptors, as judged by their displacement of [125I]-BH-CCK-8S in a radioligand binding assay and by their activity in an isolated, perfused rat stomach bioassay, respectively. 2-(5-Cyclohexyl-1-(2-cyclopentyl-2-oxo-ethyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-N-(3-(5-oxo-2,5-dihydro- [1,2,4]oxadiazol-3-yl)-phenyl)-acetamide (47) was identified as the most effective compound stemming from this approach, proving to be a potent inhibitor of pentagastrin-stimulated gastric acid secretion in rats and dogs by intravenous bolus as well as by enteral administration.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm070139l